While talks broke off late last year, Thermo Fisher Scientific (NYSE:TMO) is acquiring Dutch molecular-testing firm Qiagen (NYSE:QGEN) for €10.4B, including assumed debt.
Investors would get €39 for every Qiagen share, 23% higher than Monday’s closing price.
It’s the second major transaction in the healthcare sector this week after Gilead Sciences agreed to buy Forty Seven for about $4.9B to advance into cancer treatments.
https://seekingalpha.com/news/3547860-thermo-fisher-to-buy-qiagen-for-10_4b
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.